MenQuadfi

Land: Europese Unie

Taal: Fins

Bron: EMA (European Medicines Agency)

Werkstoffen:

Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid

Beschikbaar vanaf:

Sanofi Pasteur

ATC-code:

J07AH08

INN (Algemene Internationale Benaming):

meningococcal group A, C, W-135 and Y conjugate vaccine

Therapeutische categorie:

rokotteet

Therapeutisch gebied:

Meningiitti, meningokokki

therapeutische indicaties:

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.

Product samenvatting:

Revision: 8

Autorisatie-status:

valtuutettu

Autorisatie datum:

2020-11-18

Bijsluiter

504 GATEWAY TIME-OUT

Productkenmerken

504 GATEWAY TIME-OUT